Aging is a natural process leading to the progressive loss of physiological functions,
increased inflammatory status, decreased naïve immune T-cell population, increased
mutational events and epigenetic modifications resulting in an impaired health status.
With the aging of the population, the number of older patients with hematologic disease
will continue to increase. Since life expectancy for an 80 year-old patient can vary
between 3 and 11 years according to his health status, it is of major importance to
identify patients without irreversible comorbidities who have a significant life-expectancy
and who would benefit most from the optimal treatment of the hematologic disease.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to European Journal of Internal MedicineAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
Article info
Publication history
Published online: November 27, 2018
Identification
Copyright
© 2018 Published by Elsevier B.V. on behalf of European Federation of Internal Medicine.
